This issue reminds us that humankind remains the enduring question, and diversity in clinical trials is the answer (even if ...
Johnson & Johnson has reported late‑breaking phase 2 results showing that nipocalimab met the primary endpoint of reducing ...
JJP Biologics has reported positive interim findings from its ongoing phase 1b study of nebaprubart (JJP‑1212) in patients with linear IgA disease, a rare autoantibody‑driven blistering disorder with ...
Deep Science Ventures (DSV) and Medicines Discovery Catapult (MDC) have formed a strategic partnership to tackle one of ...
Aragen has completed the technology transfer and first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead ...
Resolution Therapeutics has welcomed new four‑year follow‑up data from the University of Edinburgh’s MATCH trial, which ...
Pierre Fabre Laboratories has received a positive opinion from the European Medicines Agency’s CHMP recommending approval of ...
Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma HaemaLogiX has opened patient enrolment for its phase 1 Koala clinical trial at the Peter MacCallum Cancer ...
Phase 2 bridge data show consistent outcomes in patients with impaired kidney function Oncopeptides has reported new phase 2 data supporting the use of Pepaxti in relapsed refractory multiple myeloma ...
Oncopeptides has reported new phase 2 data supporting the use of Pepaxti in relapsed refractory multiple myeloma patients with moderate to severe renal impairment, a group that accounts for around ...
Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results